pharma news today glp-1 2025 A network meta-analysis backed weight-loss benefits with several receptor agonists, with less certainty for newer-generation agents. Read more at the link in bio Alarming rise in weight loss

A third option is endoscopy with culture, which

Introduction: While glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have become increasingly prescribed, use is often inhibited by the...

By Connor Iapoce The FDA accepted the NDA for oral semaglutide 25 mg, a potentially revolutionary daily treatment for weight management and cardiovascular risk reduction

This guide applies to all GLP-1 medications (including Ozempic, Wegovy, Mounjaro, and Saxenda).

Sandoz CEO Richard Saynor describes Canada as the world's second-largest GLP-1 market, raising cross-border supply concerns as generics near approval.

Enter vial size, BAC water & target research amount get draw volume instantly